Scalable continuous-flow electroporation platform enabling T cell transfection for cellular therapy manufacturing
Масштабируемая проточная платформа для электропорации, обеспечивающая трансфекцию T-клеток при производстве клеточных терапевтических препаратов
2023-04-26
SCID: 54.1/45kmw5m7
Discuss with AI
CRISPR/Cas9T cell transfectioncellular therapy manufacturingcontinuous-flow electroporationnon-viral cell engineering
Figures from the paper
Abstract (AI)
Viral vectors represent a bottleneck in the manufacturing of cellular therapies. Electroporation has emerged as an approach for non-viral transfection of primary cells, but standard cuvette-based approaches suffer from low throughput, difficult optimization, and incompatibility with large-scale cell manufacturing. Here, we present a novel electroporation platform capable of rapid and reproducible electroporation that can efficiently transfect small volumes of cells for research and process optimization and scale to volumes required for applications in cellular therapy. We demonstrate delivery of plasmid DNA and mRNA to primary human T cells with high efficiency and viability, such as > 95% transfection efficiency for mRNA delivery with < 2% loss of cell viability compared to control cells. We present methods for scaling delivery that achieve an experimental throughput of 256 million cells/min. Finally, we demonstrate a therapeutically relevant modification of primary T cells using CRISPR/Cas9 to knockdown T cell receptor (TCR) expression. This study displays the capabilities of our system to address unmet needs for efficient, non-viral engineering of T cells for cell manufacturing.
Key Findings
1
A continuous-flow electroporation platform enables rapid, reproducible transfection of primary human T cells across research-scale and manufacturing-scale volumes.
2
CRISPR/Cas9 delivery enabled therapeutically relevant knockdown of T-cell receptor expression in primary T cells.
3
Scaling methods reached an experimental throughput of 256 million cells per minute, supporting large-scale cellular therapy manufacturing.
4
The platform efficiently delivers plasmid DNA and mRNA to primary T cells while maintaining high cell viability.
5
mRNA delivery achieved over 95% transfection efficiency with less than 2% loss of viability relative to control cells.
Research Object
Primary human T cells undergoing continuous-flow electroporation for non-viral cellular therapy engineering
Research Subject
Scalable, rapid, reproducible transfection and therapeutic genetic modification of T cells, including plasmid DNA/mRNA delivery and CRISPR/Cas9-mediated TCR knockdown, while preserving cell viability
Publication Details
Publication Date
2023-04-26
Journal
Publisher
ISSN
Cited by
46
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest